tion occurred in 22% of patients.
The reasons for discontinuation included peripheral neuropathy (8%),
asthenic conditions (3%) and thrombocytopenia and diarrhea (each 2%). In
total, 2% of the patients died and the cause of death was considered by the
investigator to be possibly related to study drug: including reports of
cardiac arrest, congestive heart failure, respiratory failure, renal
failure, pneumonia and sepsis. This integrated analysis does not include
the Phase 3, VELCADE plus DOXIL study.
For more information about VELCADE clinical trials, patients and
physicians can contact the Millennium Medical Product Information
Department at 1-866-VELCADE (1-866-835-2233).
Millennium Pharmaceuticals, Inc., a leading biopharmaceutical company
based in Cambridge, Mass., markets VELCADE, a novel cancer product, and has
a robust clinical development pipeline of product candidates. Millennium's
research, development and commercialization activities are focused in two
therapeutic areas: oncology and inflammation. By applying its knowledge of
the human genome, understanding of disease mechanisms and industrialized
drug discovery platform, Millennium is developing an exciting pipeline of
innovative product candidates. Millennium's website is http://www.millennium.com.
Millennium has announced that it has entered into an Agreement and Plan of
Merger, dated as of April 10, 2008, with Takeda America Holdings, Inc., a
New York corporation ("Takeda"), and Mahogany Acquisition Corp., a Delaware
corporation and a wholly-owned subsidiary of Takeda ("Merger Sub"),
pursuant to which Merger Sub will make a cash tender offer (the "Offer") to
purchase all of the issued and outstanding shares of Millennium common
stock, and Millennium will become a wholly-owned subsidiary of Takeda.
Use of Forward-Looking Statements
This material contains "forward-looking statements" that involve
significant risks and uncer
Page: 1 2 3 4 5 6 7 Related biology technology :1
|SOURCE Millennium Pharmaceuticals, Inc.|
Copyright©2008 PR Newswire.
All rights reserved
. Millennium Announces $200,000 Purchase Order From Greek Distributor2
. Millennium Biotechnologies, Inc. Signs Marketing and Distribution Agreement with Ferring Pharmaceuticals3
. Millennium Over-Delivers on 2007 Goals and Financial Guidance4
. Millennium Biotechnologies Group Reports 40% Sales Increase for Resurgex Product Line in Greek Market5
. Millennium Announces 2008 Goals for Growth, Building on Record 2007 Results6
. Millennium to Receive $40 Million Milestone Payment for Achievement of Sales Threshold for Velcade(R) (Bortezomib) for Injection7
. Millennium Ships and Records the First $200,000 of Revenue Generated From the Five-Year $20,000,000 Exclusive Purchase Order8
. Millennium Biotechnologies, Inc. Launches SURGEX(TM) the First Scientifically Validated Sports Nutritional Product Created from the Medical Markets9
. Millennium Research Group Offers New Marketrack Service that Tracks European Dental Implant Market10
. Millennium Reports Outstanding Third-Quarter Results Driven by VELCADE(R) (Bortezomib) for Injection Sales11
. Millennium to Webcast Third-Quarter 2007 Financial and Operational Results